Goldman Sachs Group Inc Protalix Bio Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $580 Billion
- Q2 2024
A detailed history of Goldman Sachs Group Inc transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 461,958 shares of PLX stock, worth $554,349. This represents 0.0% of its overall portfolio holdings.
Number of Shares
461,958
Previous 92,424
399.82%
Holding current value
$554,349
Previous $116,000
365.52%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding PLX
# of Institutions
65Shares Held
5.8MCall Options Held
103KPut Options Held
4.6K-
Israel Englander Millennium Management LLC | New York, Ny811KShares$973,3920.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny805KShares$965,5200.0% of portfolio
-
Northern Trust Corp Chicago, IL423KShares$507,8550.0% of portfolio
-
Gsa Capital Partners LLP London, X0401KShares$481,4920.03% of portfolio
-
Black Rock Inc. New York, NY333KShares$399,8050.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $59.7M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...